TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是观察在使用吸入性皮质类固醇控制哮喘良好的儿童中停止使用每日吸入性皮质类固醇（ICS）治疗是否安全。 这项研究的另一个目的是观察在需要急救药物时同时使用沙丁胺醇和吸入性皮质类固醇是否比单独使用沙丁胺醇更能预防哮喘发作。 研究的第三个目的是了解年龄，性别，哮喘和过敏家族史，过敏程度和遗传学等个人特征可能与每种药物的良好或不良反应有关。 将对您的血液样本进行与您的呼吸系统、过敏和哮喘药物相关的化学和细胞特性检测。此外，还将对您的血液进行基因分析。 如果您的亲生父母同意参与本研究的遗传学部分，将要求他们签署单独的知情同意书。 这些发现可能有助于研究人员了解某些基因与儿童对研究药物的反应之间的可能联系。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to see if it is safe to stop using daily inhaled corticosteroid (ICS) therapy in children who are under good asthma control using inhaled corticosteroids. Another purpose of the study is to see if using both albuterol and inhaled corticosteroids whenever rescue medicine is needed will provide better protection against asthma attacks than using albuterol alone. A third purpose of the research study is to see what individual characteristics like age, gender, family history of asthma and allergies, the degree of allergy, and genetics, may be linked with either a good or poor response to each of the medications. Your blood sample will be tested for chemical and cellular properties related to your respiratory system, allergies, and asthma medications. In addition, a genetic analysis will be performed on your blood. Your biological parent will be asked to sign a separate consent if they agree to participate in the genetics portion of this study. These findings may help investigators to understand possible links between certain genes and how children respond to the study medications.